CAPTRUST Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.3M | Buy |
32,092
+18,288
| +132% | +$8.53M | 0.03% | 444 |
|
|
2025
Q4 | $6.26M | Buy |
13,804
+1,730
| +14% | +$746K | 0.01% | 610 |
|
|
2025
Q3 | $4.73M | Sell |
12,074
-1,238
| -9% | -$517K | 0.01% | 661 |
|
|
2025
Q2 | $5.93M | Sell |
13,312
-218
| -2% | -$100K | 0.01% | 580 |
|
|
2025
Q1 | $6.56M | Buy |
13,530
+1,482
| +12% | +$691K | 0.02% | 520 |
|
|
2024
Q4 | $4.85M | Sell |
12,048
-2,361
| -16% | -$1.09M | 0.01% | 555 |
|
|
2024
Q3 | $6.7M | Buy |
14,409
+307
| +2% | +$147K | 0.02% | 460 |
|
|
2024
Q2 | $6.61M | Sell |
14,102
-2,546
| -15% | -$1.11M | 0.02% | 442 |
|
|
2024
Q1 | $6.96M | Sell |
16,648
-5,461
| -25% | -$2.31M | 0.03% | 421 |
|
|
2023
Q4 | $9M | Buy |
22,109
+3,245
| +17% | +$1.2M | 0.03% | 391 |
|
|
2023
Q3 | $6.56M | Sell |
18,864
-2,210
| -10% | -$773K | 0.03% | 431 |
|
|
2023
Q2 | $7.42M | Buy |
21,074
+528
| +3% | +$178K | 0.03% | 383 |
|
|
2023
Q1 | $6.47M | Buy |
20,546
+1,052
| +5% | +$316K | 0.03% | 395 |
|
|
2022
Q4 | $5.63M | Sell |
19,494
-26
| -0.1% | -$7.92K | 0.03% | 409 |
|
|
2022
Q3 | $5.65M | Sell |
19,520
-930
| -5% | -$268K | 0.03% | 372 |
|
|
2022
Q2 | $5.76M | Buy |
20,450
+1,012
| +5% | +$271K | 0.04% | 340 |
|
|
2022
Q1 | $5.07M | Buy |
19,438
+2,752
| +16% | +$653K | 0.03% | 365 |
|
|
2021
Q4 | $3.66M | Sell |
16,686
-2,612
| -14% | -$508K | 0.03% | 430 |
|
|
2021
Q3 | $3.5M | Buy |
19,298
+3,685
| +24% | +$719K | 0.03% | 394 |
|
|
2021
Q2 | $3.15M | Buy |
15,613
+10,833
| +227% | +$2.27M | 0.03% | 382 |
|
|
2021
Q1 | $1.03M | Buy |
4,780
+3,107
| +186% | +$682K | 0.01% | 690 |
|
|
2020
Q4 | $395K | Sell |
1,673
-2,938
| -64% | -$674K | 0.01% | 922 |
|
|
2020
Q3 | $1.26M | Buy |
4,611
+647
| +16% | +$178K | 0.02% | 439 |
|
|
2020
Q2 | $1.14M | Buy |
3,964
+2,248
| +131% | +$609K | 0.02% | 464 |
|
|
2020
Q1 | $387K | Buy |
1,716
+752
| +78% | +$173K | 0.01% | 648 |
|
|
2019
Q4 | $212K | Buy |
964
+736
| +323% | +$149K | ﹤0.01% | 961 |
|
|
2019
Q3 | $39K | Buy |
228
+6
| +3% | +$1.06K | ﹤0.01% | 1077 |
|
|
2019
Q2 | $41K | Buy |
222
+149
| +204% | +$26K | ﹤0.01% | 1052 |
|
|
2019
Q1 | $13K | Sell |
73
-21
| -22% | -$3.88K | ﹤0.01% | 1323 |
|
|
2018
Q4 | $16K | Sell |
94
-19
| -17% | -$3.29K | ﹤0.01% | 1090 |
|
|
2018
Q3 | $22K | Buy |
113
+8
| +8% | +$1.43K | ﹤0.01% | 975 |
|
|
2018
Q2 | $18K | Buy |
105
+52
| +98% | +$8.06K | ﹤0.01% | 990 |
|
|
2018
Q1 | $8K | Sell |
53
-2
| -4% | -$327 | ﹤0.01% | 1091 |
|
|
2017
Q4 | $8K | Buy |
55
+18
| +49% | +$2.67K | ﹤0.01% | 1053 |
|
|
2017
Q3 | $6K | Buy |
+37
| New | +$5.57K | ﹤0.01% | 476 |
|
Other funds holding VRTX
VCM
VPM
CAPTRUST Financial Advisors's VRTX Position: Q1 2026 in Review
CAPTRUST Financial Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 132% in Q1 2026, buying an estimated $8.53M and bringing the position to 32,092 shares worth $14.3M. The position accounts for 0.03% of the portfolio, ranked #444.
CAPTRUST Financial Advisors first reported a position in VRTX in Q3 2017 and has held it in 35 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- CAPTRUST Financial Advisors held 32,092 shares of Vertex Pharmaceuticals worth $14.3M as of Q1 2026.
- CAPTRUST Financial Advisors bought 18,288 Vertex Pharmaceuticals shares in Q1 2026, an estimated $8.53M.
- Vertex Pharmaceuticals made up 0.03% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #444 holding.
- CAPTRUST Financial Advisors first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 35 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.